Vitamin C with Chemotherapy and Radiation for Lung Cancer
(XACT-LUNG Trial)
Trial Summary
What is the purpose of this trial?
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy for non-small cell lung cancer. The standard therapy is radiation therapy combined with carboplatin and paclitaxel (types of chemotherapy). All subjects will receive high-dose ascorbate in addition to the standard therapy.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications like warfarin, flecainide, methadone, amphetamines, quinidine, and chlorpropamide unless a substitution is possible. If you are on these medications and cannot switch, you may not be eligible to participate.
What data supports the effectiveness of the treatment involving Vitamin C with Chemotherapy and Radiation for Lung Cancer?
Research shows that combining paclitaxel and carboplatin with radiation therapy can improve local and systemic control of non-small cell lung cancer, potentially increasing survival rates. This combination has been found to be relatively safe and more active compared to some standard treatments.12345
Is the combination of Vitamin C, chemotherapy, and radiation therapy safe for lung cancer treatment?
What makes the treatment of Vitamin C with chemotherapy and radiation for lung cancer unique?
This treatment is unique because it combines Vitamin C with standard chemotherapy drugs (carboplatin and paclitaxel) and radiation therapy, potentially enhancing the effectiveness of the chemotherapy and radiation by acting as a radiosensitizer, which may improve local and systemic control of the cancer.12345
Eligibility Criteria
This trial is for adults with non-small cell lung cancer who are healthy enough for chemotherapy and radiation, have a measurable tumor of at least 1 cm by CT or MRI, and not pregnant. They must have normal platelet counts and kidney function, no severe pleural effusion, no G6PD deficiency, not on certain medications like warfarin or insulin, and not HIV positive on antiretroviral therapy.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive high-dose ascorbate with standard chemotherapy and radiation therapy
Consolidation Chemotherapy
Participants receive 2 extra cycles of chemotherapy after combined therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Follow-up
Participants have life-long follow-up for the study
Treatment Details
Interventions
- Ascorbic Acid (Other)
- Carboplatin (Alkylating agents)
- Paclitaxel (Anti-metabolites)
- Radiation Therapy (Radiation)
Carboplatin is already approved in United States, European Union, Canada for the following indications:
- Ovarian cancer
- Testicular cancer
- Lung cancer
- Head and neck cancer
- Brain cancer
- Ovarian cancer
- Small cell lung cancer
- Ovarian cancer
- Small cell lung cancer
- Testicular cancer